Bolt Biotherapeutics - Finding better ways to treat cancer
At Bolt, we are leveraging the immune system for a better way to treat cancer. Our approach works with a person’s body, not against it. We do this by using the innate immune system, which has evolved to recognize sequences associated with …
Bolt Biotherapeutics Reports Third Quarter 2024 Financial
3 days ago · About Bolt Biotherapeutics, Inc. Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline ...
Bolt Biotherapeutics Reports Third Quarter 2024 Financial
3 days ago · Bolt Biotherapeutics’ Boltbody ISAC platform harnesses the precision of antibodies with the power of the innate and adaptive immune system to generate a productive anti-cancer response.
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results …
3 days ago · Bolt Biotherapeutics’ Boltbody ISAC platform harnesses the precision of antibodies with the power of the innate and adaptive immune system to generate a productive anti-cancer response.
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC …
About Bolt Biotherapeutics, Inc. Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a ...
Bolt Biotherapeutics, Inc. (BOLT) Stock Price, News, Quote
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer.
About Us - Bolt Biotherapeutics
Bolt Biotherapeutics is a clinical-stage biotech company leveraging the immune system for a better way to treat cancer. The company is developing novel immunotherapies using an approach that uses foreign patterns to trigger the innate immune system, which then teaches the immune system to recognize and kill cancer.
Pipeline - Bolt Biotherapeutics
View the robust Bolt Biotherapeutics pipeline of immune-stimulated, myeloid-engaging therapeutics targeting urgent unmet patient needs.
Corporate Overview - Bolt Biotherapeutics
May 14, 2024 · Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development.
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 …
BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid tumors.
- Some results have been removed